Manoj Parulekar

Dr. Manoj Parulekar


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CSChristina Stathopoulos
Christina Stathopoulos
LRLivia Lumbroso-Le Lumbroso-Le Rouic
Livia Lumbroso-Le Lumbroso-Le Rouic
AMAnnette C. Moll
Annette C. Moll
MPManoj Parulekar
Manoj Parulekar
PMPhilippe Maeder
Philippe Maeder
Francis L. MunierFrancis L. Munier
Francis L. Munier
Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.

19 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
ESEdward Stone
Edward Stone
CRClaudia Román-Montañana
Claudia Román-Montañana
JAJoseph Abbott
Joseph Abbott
Trevor R.P. ColeTrevor R.P. Cole
Trevor R.P. Cole
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.

1 January 2014 in Ophthalmic Plastic & Reconstructive Surgery
Verified
Journal Article
Closed access
DTDipti M.B.Bch. Trivedi
Dipti M.B.Bch. Trivedi
MMMaureen McCalla
Maureen McCalla
ZSZoe G.C.S.E. Squires
Zoe G.C.S.E. Squires
MPManoj Parulekar
Manoj Parulekar
Purpose: Congenital anophthalmia and postenucleation socket contracture are difficult conditions that require serial socket expansion with the use of hydrogel expanders and custom-made conformers along with temporary tarsorrhaphy. Methods: The authors undertook a part prospective case review of all children undergoing temporary tarsorrhaphy using cyanoacrylate glue over a 3-year period at a tertiary specialist children’s hospital. Results: They report a series of 7 children undergoing temporary tarsorrhaphy with cyanoacrylate glue instead of the conventional suturing technique. Indications were socket expansion (n = 4), fornix deepening (n = 2), prosthesis reposition, and prolapsed conjunctiva following enucleation (n = 1).The age range was 3 weeks to 14 years (mean, 2.7 years). The glue tarsorrhaphy lasted between 0.5 and 13 weeks (mean, 4.5 weeks). There were no adverse outcomes, and the glue tarsorrhaphy was tolerated well in all cases, with relative ease of reapplication of glue in clinic. Conclusions: Their study demonstrates that this technique allows quick and efficient temporary tarsorrhaphy with relative ease of reapplication in a clinic setting, avoiding the need for multiple general anesthetics.

1 February 2014 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
CFCharles P. Lim Fat
Charles P. Lim Fat
SLSam Yuen Sum Lee
Sam Yuen Sum Lee
MBMarie-Anne Brundler
Marie-Anne Brundler
CSChristopher M. Scott
Christopher M. Scott
MPManoj Parulekar
Manoj Parulekar

4 September 2013 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
RBRuchika Batra
Ruchika Batra
JAJoseph Abbott
Joseph Abbott
HJHelen Jenkinson
Helen Jenkinson
JAJohn R. Ainsworth
John R. Ainsworth
TCTrevor Cole
Trevor Cole
PKPamela Kearns
Pamela Kearns

7 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JPJesse Panthagani
Jesse Panthagani
PMPablo Montecinos
Pablo Montecinos
JLJuan P López
Juan P López
MPManoj Parulekar
Manoj Parulekar